Abstract: Two of these substitutions are associated with lamivudine resistance (LVDr) in the tyrosine-methionine-aspartate-aspartate (YMDD) motif (rtM204V and rtL180M), whereas the other occurs at one or more positions specifically associated with ETV resistance (ETVr): rtT184, rtS202, or rtM250.
[Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].
Abstract: RESULTS: Lamivudine resistant mutation was detected in 103 patients, and the major mutations included rtL180M+rtM204V and rtM204I, accounting for 58.3% and 22.3%, respectively.
Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant.
Abstract: RESULTS: The mutations rtF166L/sF158Y (lamivudine-associated, compensatory) and rtl169T/sF161L (entecavir-associated, primary) acting alone, and the mutations rtV173L/sE164D (lamivudine-associated, compensatory) and rtSilent/sD144E (antibody escape-associated) each when combined with rtM204V/sl195M (lamivudine-associated, primary) led to decreases in antibody reactivity to epitopes in the first or second loop, or in both loops.
Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA.
PMID: 18606836
2008
Antimicrobial agents and chemotherapy
1Abstract: Only the genomes from the last biopsy specimen obtained after the emergence of lamivudine resistance contained the lamivudine resistance-associated mutations rtL180M and rtM204V (""rt"" indicates reverse transcriptase domain)."
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
PMID: 18617782
2008
European journal of gastroenterology & hepatology
Abstract: Sequence analysis revealed the presence of rtL180M and rtM204V lamivudine-resistant-associated mutations at the start of entecavir treatment.
[A five-year analysis of HBV mutations in a multidrug-resistant patient with chronic hepatitis B].
Abstract: RESULTS: Several mutations were identified in succession, including LAM-resistant mutations M204I/V and L180M+M204V, ETV-resistant mutation S202G, and HBeAg nonsense mutation G1896A.
Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
PMID: 18713056
2008
The Journal of infectious diseases
Abstract: BACKGROUND: Hepatitis B virus (HBV) establishes lamivudine resistance via the resistance-causative rtM204V/I mutation and the replication-compensatory rtL180M mutation.
Understanding the molecular basis of HBV drug resistance by molecular modeling.
Abstract: In this regard, homology modeled structure of HBV-polymerase was used for minimization, conformational search and induced fit docking followed by binding energy calculation on wild-type as well as on mutant HBV-polymerases (L180M, M204V, M204I, L180M+M204V, L180M-M204I).
Conclusion: Upward shifting favors the binding of LdT without enforcing M204 for induced fit effect, and also helps in binding to mutant M204V HBV, while M204I does not support LdT binding due to steric clash.
Table: M204V
Figure: a) Binding mode of L-FMAU-TP along with mutant
[Multiple-site analysis of HBV drug-resistant mutations in 340 patients with chronic hepatitis B].
Abstract: In naive patients treated with ETV, atleast three mutations arising at the same time are required: rtL180M + rtM204V plus either one of rtT184, rtS202 or rtM250 codon changes.
Abstract: Several major HBV-evolutionary NA-resistance pathways (rtM204I/V, rtN236T and rtA181T/V) have now been characterised.
Abstract: The rtM204V/I pathway is responsible for resistance to the L: -nucleosides, such as lamivudine (LMV), telbivudine (LdT)
HBV mutation literature information.
PMID: 
2008
Hepatology (Baltimore, Md.)
Browser Board
Co-occurred Entities
Filtrator
ViMRT